Drug or treatment

Cabozantinib clinical trials

• 38Clinical trials
• 29Countries

Newest trials

All recruiting trials (38)

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• Cabozantinib for adults with previously treated neuroendocrine tumors

  This study will see how cabozantinib works and how safe it is for adults with neuroendocrine tumors that have continued to grow after prior systemic treatment.

  Recruiting at 23 sites Ipsen · Graz and 40 other locations · NCT07314164

• Belzutifan plus zanzalintinib versus cabozantinib for recurrent advanced kidney cancer after adjuvant PD-1/L1 therapy

  This study will test whether taking belzutifan together with zanzalintinib helps people with recurrent advanced kidney cancer live longer and keep the cancer from getting worse compared with cabozantinib after prior adjuvant PD-1/L1 therapy.

  Recruiting at 127 sites Phase 3 Merck Sharp & Dohme LLC · Anchorage, Alaska and 126 other locations · NCT07227402

• Bone metastasis in clear cell kidney cancer: cabozantinib plus nivolumab feasibility and bone microenvironment study

  This study tests whether cabozantinib with nivolumab can be given safely to people with clear cell renal cell carcinoma that has spread to bone and helps us see how bone immune cells respond.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07187869

• Taking cabozantinib on a skip-days schedule instead of lowering the daily dose

  This test tries whether taking cabozantinib on a skip-days schedule gives similar drug levels, side effects, and quality of life for adults with metastatic renal cell carcinoma who are already on 20–40 mg daily.

  Recruiting Phase 2 Leiden University Medical Center · Leiden, South Holland · NCT07077161

• Digital symptom monitoring for people starting cabozantinib plus nivolumab for advanced clear-cell kidney cancer

  This project tests whether weekly digital self-reports of symptoms can help guide treatment management for adults beginning cabozantinib plus nivolumab for advanced clear-cell kidney cancer during the first three months.

  Recruiting at 3 sites Phase 4 Centre Francois Baclesse · Annecy and 18 other locations · NCT07028125

• Casdatifan plus cabozantinib versus placebo plus cabozantinib for advanced clear cell kidney cancer

  This trial tests whether adding casdatifan to cabozantinib helps adults with advanced or metastatic clear cell kidney cancer who progressed after PD‑1 or PD‑L1 immunotherapy.

  Recruiting at 191 sites Phase 3 Arcus Biosciences, Inc. · Gilbert, Arizona and 190 other locations · NCT07011719

• Nivolumab plus cabozantinib for older adults with kidney cancer

  This trial tests the combination of nivolumab and cabozantinib in people aged 70 and older with metastatic clear-cell kidney cancer to see how it is used and tolerated in routine care.

  Recruiting Phase 4 Gustave Roussy, Cancer Campus, Grand Paris · Angers and 6 other locations · NCT06934057

• Adding cabozantinib to cemiplimab for adolescents and adults with advanced adrenocortical cancer

  This test sees if adding the targeted drug cabozantinib to the immunotherapy cemiplimab helps adolescents and adults with advanced, unresectable, recurrent, or metastatic adrenocortical cancer.

  Recruiting at 80 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 80 other locations · NCT06900595

• Combining abemaciclib and cabozantinib for treating metastatic clear cell renal cell carcinoma

  This study is testing a combination of two drugs, abemaciclib and cabozantinib, to see if they can safely help people with advanced clear cell kidney cancer.

  Recruiting at 8 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Baltimore, Maryland and 7 other locations · NCT06835972

• Sapanisertib plus cabozantinib for metastatic liver cancer with beta-catenin changes

  This trial tests whether adding sapanisertib to cabozantinib helps people with metastatic liver cancer that has a beta-catenin gene change.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Irvine, California and 3 other locations · NCT06811116

• Combination therapy to shrink plexiform neurofibromas in NF1 patients

  This trial tests whether the drugs cabozantinib and selumetinib can be safely given together to see if they help shrink progressive or painful plexiform neurofibromas in adolescents and adults with NF1.

  Recruiting at 8 sites Phase 1 University of Alabama at Birmingham · Birmingham, Alabama and 7 other locations · NCT06502171

• Comparing targeted therapy and chemotherapy for thyroid cancer

  This study is testing whether a new targeted therapy works better than standard chemotherapy for patients with a specific type of thyroid cancer that has a BRAF V600E mutation.

  Recruiting at 289 sites Phase 3 Eastern Cooperative Oncology Group · Anchorage, Alaska and 306 other locations · NCT06475989

• Using cabozantinib with ifosfamide to treat Ewing's sarcoma and osteosarcoma

  This study is testing if a new combination of cabozantinib and high-dose ifosfamide can help children and young adults with Ewing's sarcoma and osteosarcoma that hasn't responded to previous treatments.

  Recruiting at 4 sites Phase 1 Children's Hospital of Philadelphia · San Francisco, California and 3 other locations · NCT06156410

• Cabozantinib plus pembrolizumab for advanced or unresectable adrenal cortical cancer

  This trial tests whether adding cabozantinib to pembrolizumab can shrink or control advanced, metastatic, or unresectable adrenal cortical cancer.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT06006013

• Higher dose of cabozantinib for advanced kidney cancer

  This study is testing whether a higher dose of cabozantinib can help people with advanced kidney cancer who didn’t respond to previous treatment with the same drug.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT05931393

• Comparing two treatments for metastatic midgut neuroendocrine tumors

  This study is testing whether a retreatment with a specific type of radiation therapy or a daily pill works better for people with advanced midgut neuroendocrine tumors who have already had radiation therapy before.

  Recruiting at 40 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 42 other locations · NCT05773274

• Combination treatment for advanced clear cell kidney cancer

  This study is testing a new combination of treatments for people with advanced clear cell kidney cancer to see if it is safe and effective.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05663710

• Combining cabozantinib with Lutetium-177 for advanced prostate cancer treatment

  This study is testing if combining cabozantinib with Lutetium-177 can safely help people with advanced prostate cancer.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT05613894

• Combining cabozantinib and pembrolizumab for lung cancer maintenance therapy

  This study is testing if combining cabozantinib with pembrolizumab can help people with advanced squamous non-small cell lung cancer stay healthy after their initial treatment.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT05613413

• Combining Cabozantinib and Dostarlimab for Recurrent Gynecologic Carcinosarcoma

  This study is testing if combining two drugs, Cabozantinib and Dostarlimab, can help people with recurrent gynecologic carcinosarcoma who have already had chemotherapy.

  Recruiting Phase 1/2 University of Alabama at Birmingham · Birmingham, Alabama · NCT05559879

• Using Cabozantinib to treat recurrent or progressive meningioma

  This study is testing if Cabozantinib can help people with recurring or worsening meningioma, a type of brain tumor, feel better after other treatments haven’t worked.

  Recruiting at 3 sites Phase 2 Baptist Health South Florida · Miami, Florida and 2 other locations · NCT05425004

• Alternative dosing schedule for cabozantinib in advanced kidney and neuroendocrine tumors

  This study is testing a new way to give cabozantinib to see if it helps people with advanced kidney cancer and neuroendocrine tumors feel better and stay safe while being treated.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05263050

• Combining pembrolizumab and cabozantinib for advanced sarcomas

  This study is testing if combining two treatments, pembrolizumab and cabozantinib, can help people with advanced types of sarcoma feel better and improve their condition.

  Recruiting at 6 sites Phase 2 Institut Bergonié · Bordeaux and 9 other locations · NCT05182164

• Combining cabozantinib and nivolumab to treat advanced melanoma and head and neck cancer

  This study is testing a combination of two cancer drugs, cabozantinib and nivolumab, to see if they can help people with advanced melanoma or head and neck cancer while also looking at how to better match treatments to patients based on their tumor characteristics.

  Recruiting at 211 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 231 other locations · NCT05136196

• Using cabozantinib to prevent recurrence in high-risk pediatric solid tumors

  This study is testing if the drug cabozantinib can help prevent high-risk pediatric solid tumors, like neuroblastoma and sarcoma, from coming back after treatment.

  Recruiting at 6 sites Phase 2 Nationwide Children's Hospital · Birmingham, Alabama and 5 other locations · NCT05135975

• Dendritic cell vaccine treatment for kidney cancer

  This study is testing a new vaccine combined with a medication to see if it can help people with early-stage kidney cancer boost their immune response before surgery.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT05127824

• Combining Tumor Treating Fields with Cabozantinib or Pembrolizumab and Nab-Paclitaxel for Advanced Solid Tumors

  This study is testing a new treatment that combines tumor treating fields with two different cancer drugs to see if it helps people with advanced solid tumors in the abdomen or chest.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT05092373

• Combination treatment of cabozantinib and lanreotide for advanced gastroenteropancreatic neuroendocrine tumors

  This study is testing a new combination of daily cabozantinib and monthly lanreotide to see if it helps people with advanced gastroenteropancreatic neuroendocrine tumors who haven't responded to previous treatments.

  Recruiting at 11 sites Phase 1/2 National Health Research Institutes, Taiwan · Changhua and 10 other locations · NCT05048901

• Combining nivolumab, ipilimumab, and cabozantinib for untreated kidney cancer that has spread to the brain

  This trial tests whether adding the oral drug cabozantinib to two immunotherapy medicines (nivolumab and ipilimumab) helps people with untreated renal cell carcinoma brain metastases live longer or have their brain tumors shrink.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05048212

• Combining atezolizumab and cabozantinib for treating recurrent or metastatic osteosarcoma in adolescents and young adults

  This study tests if combining two medications, atezolizumab and cabozantinib, can help adolescents and young adults with recurrent or metastatic osteosarcoma live longer and feel better.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Boston, Massachusetts and 1 other locations · NCT05019703

• Evaluating Cabozantinib and Temozolomide for Lung and GEP Neuroendocrine Tumors

  This study is testing if combining two medications, Cabozantinib and Temozolomide, can help people with advanced lung and gastroenteropancreatic neuroendocrine tumors who haven't responded to other treatments.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples, Campania · NCT04893785

• Combining cabozantinib and enfortumab vedotin for advanced bladder cancer

  This study is testing a new combination of two drugs, cabozantinib and enfortumab vedotin, to see if it can help people with advanced bladder cancer feel better and live longer.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT04878029

• Combining cabozantinib with ipilimumab/nivolumab and TACE for liver cancer treatment

  This study is testing if combining cabozantinib with two immune therapies and a specific type of chemo can help people with liver cancer who can’t have surgery feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT04472767

• Using cabozantinib to treat liver cancer that has returned after transplant

  This study is testing if cabozantinib can help people with liver cancer that has come back after a liver transplant.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT04204850

• Combining immunotherapy and targeted therapy for rare bladder tumors

  This study is testing a new combination of treatments for people with rare bladder tumors that have spread, to see if it helps them live longer and feel better.

  Recruiting at 222 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 581 other locations · NCT03866382

• Combining cabozantinib and durvalumab for advanced gastrointestinal cancers

  This study is testing a new combination of two cancer drugs, cabozantinib and durvalumab, to see if they can help people with advanced gastrointestinal cancers feel better and improve their outcomes.

  Recruiting Phase 1/2 University of Pittsburgh · Westwood, Kansas and 1 other locations · NCT03539822

• Using cabozantinib to treat advanced non-small cell lung cancer with specific gene changes

  This study is testing if cabozantinib can help people with advanced non-small cell lung cancer that has certain gene changes by shrinking tumors and slowing down cancer growth.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT01639508

Quick answers

How many clinical trials of Cabozantinib are recruiting right now?

38, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 29 countries. The most sites are in United States (29 trials), France (5 trials), Italy (4 trials), Canada (3 trials), Germany (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 1: 6, Phase 1/2: 6, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →